Viking Therapeutics CEO Buys Shares Amid Strong VTK‑001 Pipeline & Insider Confidence
Viking Therapeutics’ CEO buys shares after RSU vest, signaling confidence in VTK‑001’s obesity drug pipeline and potential FDA approval in 2027‑28.
4 minutes to read